---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016742"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T02:58:29.061699+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neuronetics Q3 revenue $16.5M (+20% YoY); raises FY2022 guidance to $63-64M

## Summary
- Q3 revenue $16.5M (+20% YoY); net loss $(7.6)M ($0.28/sh) vs $(8.2)M loss a year ago.
- Record US treatment session revenue $11.9M (+16% YoY); NeuroStar system revenue up 51% to $3.9M.
- Raised FY2022 revenue guidance to $63-64M from $60-62M; Q4 expected $16-17M.
- Received FDA 510(k) clearance for D-Tect MT Accessory; positive TMS coverage policies from CGS and NGS MACs.

## SEC filing metadata
- accession: 0001558370-22-016742
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000155837022016742/0001558370-22-016742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000155837022016742/stim-20221108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016742
- JSON: https://secwatch.observer/filing/0001558370-22-016742.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016742.txt

## Key facts
- Earnings Releases
  Neuronetics, Inc. reported the three and nine months ended September 30, 2022 results: revenue $16.5 million, net income $(7.6) million, or $(0.28) per share, EPS $(0.28) per share. Guidance raised.
  - Period: the three and nine months ended September 30, 2022
  - Revenue: $16.5 million
  - Net income: $(7.6) million, or $(0.28) per share
  - EPS: $(0.28) per share
  - Guidance: raised
  - Result: reported results
  source text: therapies in the world, today announced its financial and operating results for the third quarter of 2022. Third Quarter 2022 Highlights ● Third quarter 2022 revenue of $16.5 million, represents a 20% increase as compared to the third quarter 2021 ● Achieved record quarterly U.S. treatment session revenue of $11.9 million in the third quarter 2022, compared
  evidence_url: https://www.sec.gov/Archives/edgar/data/1227636/000155837022016742/0001558370-22-016742-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.